Immunological monitoring of cancer vaccine therapy

Bibliography

• QIN Z, BLANKENSTEIN T: A cancer immunosurveillance controversy. Nat. Innnunol. (2004) 5(1):3–4.
   Google Scholar
• SCHREIBER RD, OLD LJ, HAYDAY AC, SMYTH MJ: Response to 'A cancer immunosurveillance controversy'. Nat. Innnunol. (2004) 5(1):4–5.
   Web of Science ®Google Scholar
• DUNN GP, BRUCE AT, IKEDA H, OLD LJ, SCHREIBER RD: Cancer immunoediting: from immunosurveillance to tumour escape. Nat. Inununol. (2002) 3(11):991–998.
   PubMed Web of Science ®Google Scholar
• BOON T, VAN BAREN N:Immunosurveillance against cancer and immunotherapy-synergy or antagonism? N Engl. J. Med. (2003) 348:252–254.
   Google Scholar
• VAN DER BRUGGEN P,TRAVERSARI C, CHOMEZ P et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643–1647.
   PubMed Web of Science ®Google Scholar
• BOON T, VAN DER BRUGGEN P: Human tumour antigens recognized by T lymphocytes. J. Exp. Med. (1996) 183(3):725–729.
   PubMed Web of Science ®Google Scholar
• VALMORI D, SCHEIBENBOGEN C, DUTOIT V et al.: Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RAHCCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. (2002) 62(6):1743–1750.
   PubMed Web of Science ®Google Scholar
• •This work is the first to show direct ex vivo tumour lytic activity of peripheral, TAA-specific T cells.
   Google Scholar
• DURRANT LG, SPENDLOVE I: Cancer vaccines entering Phase III clinical trials. Expert Opin. Ernerg. Drugs (2003) 8(2)489–500.
   Google Scholar
• SCHEIBENBOGEN C, LETSCH A, SCHMITTEL A, ASEMISSEN AM, THIEL E, KEILHOLZ U: Rational peptide-based tumour vaccine development and T cell monitoring. Sernin. Cancer Biol. (2003) 13(6):423–429.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU, J, PALUCKA AK, DHODAPKAR M et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. (2001) 61(17):6451–6458.
   PubMed Web of Science ®Google Scholar
• FONG L, HOU Y, RIVAS A et al: Altered peptide ligand vaccination with F1t3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Nati Acad. Sci. USA (2001) 98(15):8809–8814.
   PubMed Web of Science ®Google Scholar
• COULIE PG, KARANIKAS V, COLAU D et al.: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Nati Acad. Sci. USA (2001) 98(18):10290–10295.
   PubMed Web of Science ®Google Scholar
• BELLI F, TESTORI A, RIVOLTINI L et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. Clin. Oncol (2002) 20(20):4169–4180, Erratum in: J. Clin. Oncol. (2002) 20(23):4610.
   Google Scholar
• PETERSON AC, HARLIN H,GAJEWSKI TF: Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. Clin. Oncol (2003) 21(12):2342–2348.
   Web of Science ®Google Scholar
• WANG F, BADE E, KUNIYOSHI C et al: Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. (1999) 5(10):2756–2765.
   PubMed Web of Science ®Google Scholar
• SLINGLUFF CL JR, YAMSHCHIKOV G, NEESE P et al.: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. (2001) 7(10):3012–3024.
   PubMed Web of Science ®Google Scholar
• LEE P, WANG F, KUNIYOSHI J et al.: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. I Clin. Oncol. (2001) 19(18):3836–3847.
   PubMed Web of Science ®Google Scholar
• WEBER J, SONDAK VK, SCOTLAND R et al.: Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer (2003) 97(1):186–200.
   PubMed Web of Science ®Google Scholar
• LETSCH A, KEILHOLZ U, FLUCK M et al.: Vaccination can induce long-term freedom from relapsing cutaneous metastases in melanoma. (2004) (Submitted).
   Google Scholar
• NIELSEN MB, MARINCOLA FM: Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chernother. Pharmacol. (2000) 46(Suppl.):S62–S66.
   Google Scholar
• MARINCOLA FM, JAFFEE EM, HICKLIN DJ, FERRONE S: Escape of human solid tumours from T cell recognition: molecular mechanisms and functional significance. Adv. Inununol. (2000) 74:181–273.
   PubMedGoogle Scholar
• ROSENBERG SA: Progress in human tumour immunology and immunotherapy. Nature (2001) 411(6835):380–384.
   PubMed Web of Science ®Google Scholar
• KEILHOLZ U, WEBER J, FINKE JH et al.: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. I Inununother: (2002) 25(2):97–138.
   PubMed Web of Science ®Google Scholar
• •This work summarises results of the first consensus workshop on immune monitoring of cancer vaccines.
   Google Scholar
• ALTMAN JD, MOSS PA, GOULDER PJ et al.: Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 274(528094–96. Erratum in: Science (1998) 280(5371):1821.
   Google Scholar
• •This is the first manuscript to describe the utilisation of tetrarners for the analysis of antigen-specific T cell responses.
   Google Scholar
• DUTOIT V, RUBIO-GODOY V, DOUCEY MA: Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. Inununol. (2002) 168(3):1167–1171.
   Google Scholar
• LEE PP, YEE C, SAVAGE PA et al: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. (1999) 5(6):677–685.
   PubMed Web of Science ®Google Scholar
• MONSURRO V, NAGORSEN D, WANG E et al.: Functional heterogeneity of vaccine-induced CD8(+) T cells. Inununol. (2002) 168(11):5933–5942.
   Google Scholar
• NAGORSEN D, MONSURRO V, WANG E, MARINCOLA FM: Characterization of CD8(-) HLA class I/ epitope tetrameric complexes binding T cells. Inununother. (2002) 25(5):379–384.
   PubMed Web of Science ®Google Scholar
• HAANEN JB, VAN OIJEN MG, TIRION F et al.: In situ detection of virus-and tumor-specific T-cell immunity. Nat. Med. (2000) 6(9):1056–1060.
   PubMed Web of Science ®Google Scholar
• SKINNER PJ, DANIELS MA,SCHMIDT CS, JAMESON SC,HAASE AT: Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues. Inununol. (2000) 165(2):613–617.
   Google Scholar
• SKINNER PJ, HAASE AT: In situ tetramer staining. I Immunol. Methods (2002) 268(1)29–34.
   Google Scholar
• SCHMITTEL A, KEILHOLZ U, THIEL E, SCHEIBENBOGEN C: Quantification of tumor-specific T lymphocytes with the ELISPOT assay. Immunother. (2000) 23(3):289–295.
   Web of Science ®Google Scholar
• HERR W, SCHNEIDER J, LOHSE AW, MEYER ZUM BUSCHENFELDE KH, WOLFEL T: Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.' Immunol. Methods. (1996) 191(2):131–142.
   Google Scholar
• DI FABIO S, MBA WUIKE IN,KIYONO H, FUJIHASHI K,COUCH RB, MCGHEE JR: Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-gamma producing CD8+ T cells. Lit. Immunol. (1994) 6(1):11–19.
   Web of Science ®Google Scholar
• SCHEIBENBOGEN C, ROMERO P, RIVOLTINI L et al.: Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. I. Immunol. Methods (2000) 244(1-2):81–89.
   PubMed Web of Science ®Google Scholar
• ASEMISSEN AM, NAGORSEN D, KEILHOLZ U et al.: Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. Immunol. Methods (2001) 251(1-2):101–108.
   PubMed Web of Science ®Google Scholar
• SCHMITTEL A, KEILHOLZ U, BAUER S et al.: Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins.' Immunol. Methods (2001) 247(1–2):17–24.
   Google Scholar
• SUNI MA, PICKER LJ, MAINO VC: Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. I Immunol. Methods. (1998) 212(1):89–98.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. Immunol (1999) 163(3):1690–1695.
   Web of Science ®Google Scholar
• MANZ R, ASSENMACHER M, PFLUGER E, MILTENYI S, RADBRUCH A: Analysis and sorting of live cells according to secreted moleculesrelocated to a cell-surface affinity matrix. Proc. Natl. Acad. Sci. USA (1995) 92(6):1921–1925.
   PubMed Web of Science ®Google Scholar
• ASSENMACHER M, LOHNING M, SCHEFFOLD A, MANZ RA,SCHMITZ J, RADBRUCH A: Sequential production of IL-2, IFN-gamma and IL-10 by individual staphylococcal enterotwdn B-activated T helper lymphocytes. Eur. Immunol. (1998) 28(5):1534–1543.
   PubMed Web of Science ®Google Scholar
• BROSTERHUS H, BRINGS S, LEYENDECKERS H et al.: Enrichment and detection of live antigen-specific CD4 and CD8 T cells based on cytokine secretion. Eur. I Immunol. (1999) 29(12):4053–4059.
   PubMed Web of Science ®Google Scholar
• MESSELE T, ROOS MT, HAMANN D et al: Nonradioactive techniques for measurement of M vitro T-cell proliferation: alternatives to the [(3)H]thymidine incorporation assay. Clin. Diagn. Lab. Immunol. (2000) 7(4):687–692.
   PubMedGoogle Scholar
• LYONS AB, PARISH CR: Determination of lymphocyte division by flow cytometry. Immunol. Methods (1994) 171(1):131–137.
   PubMed Web of Science ®Google Scholar
• BRUNNER KT, MAUEL J,CEROTTINI JC, CHAPUIS B: Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology (1968) 14(2):181–196.
   PubMed Web of Science ®Google Scholar
• VON ZONS P, CROWLEY-NOWICK P, FRIBERG D, BELL M, KOLDOVSKY U, WHITESIDE TL: Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma. Clin. Diagn. Lab. Immunol. (1997) 4(2):202–207.
   PubMedGoogle Scholar
• MATTIS AE, BERNHARDT G, LIPP M, FORSTER R: Analyzing cytotoxicT lymphocyte activity: a simple and reliable flow cytometry-based assay. I Immunol. Methods (1997) 204(2):135–142.
   PubMed Web of Science ®Google Scholar
• RUBIO V, STUGE TB, SINGH N et al: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. (2003) 9(11):1377–1382.
   PubMed Web of Science ®Google Scholar
• BETTS MR, BRENCHLEY JM, PRICE DA et al.: Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. I Immunol. Methods (2003) 281(1-2):65–78.
   PubMed Web of Science ®Google Scholar
• GRETEN F, SLANSKY JE, KUBOTA R et al.: Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc. Nati Acad. Sci. USA (1998) 95(13):7568–7573.
   PubMed Web of Science ®Google Scholar
• OELKE M, MAUS MV, DIDIANO D, JUNE CH, MACKENSEN A, SCHNECK JP: Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. (2003) 9(5):619–624.
   PubMed Web of Science ®Google Scholar
• TOMARU U, YAMANO Y, NAGAI M et al.: Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat. Med. (2003) 9(4):469–476.
   PubMed Web of Science ®Google Scholar
• NAGORSEN D, WANG E, MARINCOLA FM, EVEN J: Transcriptional analysis of tumor-specific T-cell responses in cancer patients. Crit. Rev Immunol (2002) 22(5-6):449–462.
   PubMed Web of Science ®Google Scholar
• KAMMULA US, LEE KH, RIKER Al et al.: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. Immunol (1999) 163(12):6867–6875.
   Web of Science ®Google Scholar
• •This is the first paper applying cytokine qRT-PCR to the analysis of antigen-specific T cell responses.
   Google Scholar
• SCHENA M, SHALON D, DAVIS RW, BROWN PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 270(5235):467–470.
   PubMed Web of Science ®Google Scholar
• MONSURRO V, WANG E, YAMANO Y et al.: Quiescent phenotype of tumor-specific T cells following immunization. Blood (2004) (In Press).
   Google Scholar
• WANG E, MILLER LD, OHNMACHT GA, LIU ET, MARINCOLA FM: High-fidelity mRNA amplification for gene profiling. Nat. Biotechnol (2000) 18(4):457–459.
   PubMed Web of Science ®Google Scholar
• LEE P, WANG F, KUNIYOSHI J et al.: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. I Clin. Omni (2001) 19(18):3836–3847.
   Google Scholar
• SMITH JW 2ND, WALKER EB, FOX BA et al.: Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific1683CD8+ T-cell responses.j Clin. Oncol (2003) 21(8):1562–1573.
   Google Scholar
• SCHAED SG, KLIMEK VM, PANAGEAS KS et al.: T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund 's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res. (2002) 8(5):967–972.
   PubMed Web of Science ®Google Scholar
• SCHEIBENBOGEN C,SCHADENDORF D, BECHRAKIS NE et al.: Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int. J. Cancer (2003) 104(2):188–194.
   Google Scholar
• SLINGLUFF CL JR. PETRONI GR, YAMSHCHIKOV GV et al.: Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol (2003) 21(21):4016–4026.
   Google Scholar
• HAMANN D, ROOS MT,VAN LIER RA: Faces and phases of human CD8 T-cell development. Inununol Today (1999) 20(4):177–180.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, LENIG D, FORSTER R, LIPP M, LANZAVECCHIA A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 401(6754):708–712.
   PubMed Web of Science ®Google Scholar
• APPAY V, DUNBAR PR, CALLAN M et al.: Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. (2002) 8(4):379–385.
   PubMed Web of Science ®Google Scholar
• MONSURRO V, NIELSEN MB, PEREZ-DIEZ A et al.: Kinetics of TCR use in response to repeated epitope-specific immunization. J. Inununol (2001) 166(9):5817–5825.
   Google Scholar
• PITTET MJ, SPEISER DE, LIENARD D et al.: Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin. Cancer Res. (2001) 7(3 Suppl.):796s–803s.
   Google Scholar
• POCKAJ BA, SHERRY RM, WET JP et al.:Localization of illindium-labeled tumour infiltrating lymphocytes to tumour in patients receiving adoptive immunotherapy. augmentation with cyclophosphamide and correlation with response. Cancer (1994) 73(6):1731–1737.
   Google Scholar
• http://www.cancerimmunity.org/ peptidedatabase/Tcellepitopes.htmVAN DEN EYNDE B, VAN DER BRUGGEN P: T-cell defined tumor antigens. Acad. Cancer Inununol (2001), updated 2003.
   Google Scholar